Dan Leonard

Padraig quantified pharma +12% total and +9% ex-CDMO, with biotech double digits and GLP-1 growth of over 70%.

Mike Zhang highlighted momentum from semiconductors, data center, diverse upstream/downstream applications, pent-up demand from muted replacement cycles in prior years, and new innovation adding further catalyst.

Padraig broke down: biotech low double digits ex CDMO, small molecule mid-single digits with Asia leading. GLP-1 grew 50% (analytical 7%, CDMO 120%). Pro iQ single-quad grew 40% in QA/QC sweet spot. Very detailed decomposition.

Padraig broadened beyond memory to include global fab reshoring, downstream AI-supporting chemical processes, India fabs. Chemical ~2/3 of CAM, advanced materials ~1/3. Energy/battery also contributing. Comprehensive.

Padraig estimated $1B TAM by 2030 with about one-third addressable. Limited order benefit expected in FY2026 but conversations active with key pharma companies on shovels in the ground. Upside to forecast.

Padraig broke down China by end market: biopharma and CAM grew, food and environmental declined, small molecule stable. Revenue stable at ~$300M/quarter. FY2026 guided flat. Market share stable through direct channel visibility. Direct.

Mike Zhang highlighted strong market share, large installed base, continuous innovation beyond Intuvo into current platforms. 8850 GC as example of replacement driver. Strong innovation pipeline to sustain acceleration.

Rodney clarified simply: ~50bps last year doubled to ~100bps this year. Quick and direct reconciliation.

Padraig described stable China base. Bob broke out: pharma/food/environ up, diagnostics flat, CAM slightly down from customs delays. Comprehensive.

Bob cited prudent approach plus tougher comps in Q3. Maintained confidence in momentum. Direct but brief.

Padraig confirmed broad-based pharma improvement in QA/QC and development. Simon added cell analysis detail on academic headwinds vs biopharma strength.

Padraig detailed manufacturing exposure: no Mexico, limited Canada (BioVectra ~30% to US), China-for-China. ~$5M impact, highly mitigatable.

Padraig identified NIH funding, PFAS spending, tariffs, and IRA biopharma impact as key areas. Comprehensive coverage of policy risks.

Bob gave a clear, concise answer: instruments expected to grow low single digits in aggregate. Very direct.

Jim explained improving end market drives higher-margin reagent volumes, plus visibility into improving diagnostics customer mix. Described it as a mix scenario that gradually improves in H2.

Kim noted AI will make customers more specific in material needs, requiring more complex molecules. Bio-Techne's fifty years of manufacturing capabilities in high-quality formats positions these trends as a tailwind.

Kim quantified Q1 at 200bp headwind lapping 60% growth, Q2 at 400bp lapping 90% growth, with second half improvement. Highlighted funnel at 700 customers with 85 in clinical phases including 5 in Phase III.

Kim confirmed no change to low-single-digit full-year outlook. Fast Track news was a short-term surprise but conviction in cell therapy markets and positive end market signs support feasibility.

Jim confirmed ExoDx was a 200bp margin headwind in FY2025. The 100bp expansion reflects partial reinvestment of freed-up ExoDx resources into core growth pillars while still returning margin to investors.

Kim acknowledged near-term difficulty in maintaining 500bp premium but expressed confidence in long-range model resumption once clarity emerges on NIH, tariffs, and pharma pricing. Cited multi-year track record of differentiation.

Kim confirmed tariffs have not changed the China-for-China manufacturing strategy. Noted the Shanghai facility opened last year is now proving valuable for regional production and minimizing cross-border tariff exposure.

Kim explained most tariff exposure is from US-manufactured instruments imported to China, with a clear path to shift production to another global facility. Consumables found to have no China import tariffs. Jim added not all instruments are US-made today.

Jim clarified run rate business lags overall company growth and it is the growth pillars that drive differentiation.

Jim confirmed January improvement was specific to US academic market (~10% of revenue). Kim quantified NIH exposure: US academic ~11% of revenue, NIH-direct less than 1%.

Kim noted China is ~9% of revenue with typically 50/50 instrument-consumable mix. Jim added stimulus would be enough to flip China from declining to modestly positive growth in Q3.

Kim confirmed COMET ASP around $350,000 with no discounting needed, but declined to share unit numbers or installed base details.

Max disclosed a more conservative assumption: China IDx now expected down slightly in H2 2026 rather than prior low-single-digit growth assumption. Nothing fundamentally changed, just prudence.

Prahlad framed Synthetica as federated marketplace for validated AI models enabling lab-in-the-loop drug discovery. Near-term productivity gains plus longer-term acceleration of drug development timelines.

Prahlad maintained disciplined M&A approach with active pipeline but confirmed share buyback is the most attractive current deployment opportunity.

Max guided software to mid-single-digit organic for FY26 off a high-teens/20% comp year. New product introductions contribute modestly as software NPIs take longer to ramp.

Max pushed back, noting significant dollar weakening since March plus the volume drop of high-margin China IDx assays.

Max clarified multiyear stacks are similar Q3 vs Q4 for IDx ex-China at low double digits.

About one-third converted to SaaS. Underlying metrics (ARR, net retention, APV) continue to perform well regardless of timing dynamics.

Prahlad confidently stated full reagent and instrumentation supply chain redundancy has been established for China.

Patrick highlighted India, Latin America and reshoring across pharma and chemical, with Shawn adding strong price realization in these markets.

Shawn noted prior algorithm assumed high single digit China growth; now comfortable at mid-single digit while still hitting 6%+ long-term sales growth algorithm. Emerging markets ex-China now larger than China. Long-term optimistic given 5-year plan and GLP-1 investments.

Patrick clarified above-average growth expectation is specifically emerging markets ex-China. Emerging markets ex-China now 18% of revenue vs China 15-16%. Above corporate growth rate expected from dedicated resources and growth initiatives.

Shawn declined to give specific PA growth rate but noted extremely strong single-use technology performance, with chemical end-market softness partially offsetting bioprocessing momentum.

Patrick explained expanded mid-range strategy winning new accounts. Shawn upgraded full year to mid-to-high single digit from mid-single digit. Q3 could be mid-to-high.

Patrick acknowledged onshoring not yet material but expects it as upside in quarters/years ahead. MTD positioned later in process (after construction phase).

Shawn provided detailed China breakdown: full year down slightly, Q2 down low-to-mid single digit. Lab up low single digit, industrial down low single digit for full year.

Matt attributed the step-up to commercial execution, new products (DxI 9000, Cepheid menu), and moderating China policy headwinds; direct.

Rainer said the only commonality was resin shipments, not a molecule or single customer; direct.

Biotech exposure is 10-15% of bioprocessing, about 5% of overall Danaher. The 75% commercial volume core is the primary growth driver. Seeing improved biotech orders but early days.

Equipment investment muted for two years despite strong consumables demand, catch-up required. Reshoring is happening, timing is the question. Could be early innings of extended multi-year capital cycle.

Rainer described firming China trends: bioprocessing showed slight growth, Life Science tools seeing more stimulus activity flowing to both orders and revenue. Not at normal levels but encouraging.

Bob disclosed GLP-1 grew roughly 50% in FY2025, non-GLP-1 HVP roughly flat full year but mid-single digit in H2. Expecting acceleration to high single to low double digit for non-GLP-1 in 2026.

Eric explained growth is broader than scripts data from two major customers, citing vial components, clinical pipeline participation, geographic expansion, and generics support.

Bernard explained HVP components guidance raised from mid-single to mid-to-high single digits, with Q2 beat passed through and continued positive second half outlook. Eric added implied organic growth of 5-6% in Q3/Q4 excluding prior year incentive payment.